Alnylam Pharmaceuticals, Inc. ALNY
$157.87
-1.24%
at last close
Analyst Consensus
- Consensus Rating
- Moderate Buy (17 Buy · 6 Hold · 0 Sell)
- Average Price Target
- $322.35
- Implied Upside
- +104.2%
- Price Target Range
- $199.00 – $455.00
- Analysts (12 mo)
- 23
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| 2026-11-02 | BarclaysEliana Merle |
Maintains | Overweight | $450 → $380 |
| 2026-11-02 | Truist SecuritiesDanielle Brill |
Downgrades | Buy → Hold | $315 → $225 |
| 2026-11-02 | Canaccord GenuityWhitney Ijem |
Maintains | Buy | $429 → $323 |
| 2026-10-30 | UBSJoon Lee |
Maintains | Buy | $354 → $329 |
| 2026-10-30 | TD CowenRitu Baral |
Maintains | Buy | $482 → $354 |
| 2026-10-30 | BernsteinZhiqiang Shu |
Downgrades | Outperform → Market perform | $376 → $199 |
| 2026-10-30 | Morgan StanleyMichael Ulz |
Maintains | Equal-weight | $300 → $240 |
| 2026-10-30 | Goldman SachsSalveen Richter |
Maintains | Buy | $536 → $320 |
| 2026-10-30 | Wells FargoDerek Archila |
Maintains | Equal-weight | $253 → $220 |
| 2026-10-30 | RBC CapitalLuca Issi |
Maintains | Outperform | $345 → $280 |
| 2026-10-30 | Raymond JamesMartin Auster |
Downgrades | Strong buy → Outperform | $420 → $315 |
| 2026-10-29 | NeedhamJoseph Stringer |
Maintains | Buy | $357 → $243 |
| 2026-10-15 | UBSJoon Lee |
Assumes | Buy | $550 → $354 |
| 2026-10-14 | CitigroupEric Joseph |
Maintains | Buy | $340 → $320 |
| 2026-10-14 | Wells FargoDerek Archila |
Maintains | Equal-weight | $256 → $253 |
| 2026-10-08 | RBC CapitalLuca Issi |
Maintains | Outperform | $350 → $345 |
| 2026-09-30 | JP MorganJessica Fye |
Maintains | Overweight | $375 → $369 |
| 2026-09-21 | HC Wainwright & Co.Patrick R. Trucchio |
Reiterates | Buy | $455 |
| 2026-09-08 | JefferiesFaisal Khurshid |
Maintains | Hold | $230 → $260 |
| 2026-09-02 | HC Wainwright & Co.Patrick R. Trucchio |
Reiterates | Buy | $455 |
| 2026-08-19 | BMO CapitalDavid Lebowitz |
Initiates coverage on | Outperform | $318 |
| 2026-08-14 | Wells FargoDerek Archila |
Maintains | Equal-weight | $316 → $256 |
| 2026-08-04 | Truist SecuritiesDanielle Brill |
Maintains | Buy | $410 → $315 |
| 2026-08-04 | HC Wainwright & Co.Patrick R. Trucchio |
Maintains | Buy | $485 → $455 |
| 2026-08-03 | Raymond JamesMartin Auster |
Upgrades | Outperform → Strong buy | $420 |
| 2026-08-03 | CitigroupEric Joseph |
Maintains | Buy | $380 → $340 |
| 2026-08-03 | BarclaysEliana Merle |
Maintains | Overweight | $527 → $450 |
| 2026-07-31 | JP MorganJessica Fye |
Maintains | Overweight | $400 → $375 |
| 2026-07-31 | RBC CapitalLuca Issi |
Maintains | Outperform | $445 → $350 |
| 2026-07-31 | Morgan StanleyMichael Ulz |
Maintains | Equal-weight | $400 → $300 |
Ratings and price targets reflect each firm's most recent published action. Consensus combines the latest call from every covering firm over the past 12 months; price targets are typically 12-month horizons.
Key Stats
- Last Close
- $157.87
- Market Cap
- $21.41 billion
- 52-Week Range
- $149.18 – $495.55
- Average Volume
- 2.51 million shs
Data is delayed and provided for informational purposes only. Not investment advice. See our disclaimer.
